Found 210 clinical trials
A First-in-human Study to Assess the Safety and Tolerability of PDNO
This is a first-in-human (FIH), single-blind, placebo-controlled, single-centre study designed to assess the safety and tolerability of PDNO in healthy male and female subjects. In addition, the exposure of 1,2 propanediol (PD) will be evaluated. The study will be conducted in 2 parts: Part I: single ascending dose (SAD), 7 …
- 2 views
- 24 May, 2021
- 1 location
Pulmonary Hypertension and Measurement of Exercise Capacity Remotely
Background Hospital-based walking exercise tests are routinely used in patients with pulmonary hypertension to assess functional ability and disease progression over time. We are seeing a greater emphasis on non-face-to-face clinical assessments, where such tests cannot be conducted. It is important to identify alternative tests which can be which can …
- 0 views
- 06 Oct, 2021
- 1 location
PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation
Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the cancer DNA. PET/MR as imaging biomarkers for cardiopulmonary dysfunction with a focus on Pulmonary …
- 0 views
- 08 Oct, 2021
- 1 location
GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are
- 0 views
- 30 Nov, 2021
- 66 locations
A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
This is a two-part (Phase 2/Phase 3) study of MK-5475, an inhaled soluble guanylate cyclase stimulator, in participants with pulmonary arterial hypertension (PAH). The first part (Phase 2
- 18 views
- 08 Dec, 2021
- 40 locations
A Long-term Follow-up Study of Sotatercept for PAH Treatment
This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept in PAH.
- 0 views
- 28 Oct, 2021
- 18 locations
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas who are currently or recently treated in these trials
- 0 views
- 08 Dec, 2021
- 13 locations
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background
- 6002 views
- 21 Nov, 2021
- 310 locations
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in
- 233 views
- 02 Dec, 2021
- 159 locations
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment
Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH
- 27 views
- 01 Dec, 2021
- 298 locations